Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Squalamine - NeuBase Therapeutics

Drug Profile

Squalamine - NeuBase Therapeutics

Alternative Names: EVIZON; MSI-1256F; OHR 102; Squalamine lactate

Latest Information Update: 18 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genaera Corporation
  • Developer Genaera Corporation; NeuBase Therapeutics
  • Class Antineoplastics; Cholestanols; Eye disorder therapies; Lactates; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic macular oedema; Diabetic retinopathy; Fibrodysplasia ossificans progressiva; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 12 Jul 2019 Ohr Pharmaceutical has merged with NeuBase Therapeutics to form NeuBase Therapeutics
  • 24 Jun 2018 Biomarkers information updated
  • 16 May 2018 Vitrisa Therapeutics acquires non-exclusive rights to MAKO clinical data from Ohr Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top